Reduction of serum immunoglobulin free light chains upon rituximab (anti-cd20) treatment correlates with decreased disease activity in patients with primary sjogren's syndrome

D. M. Bruining, R. P. E. Pollard, R. Moerman, P. M. Meiners, J.M. Meijer, H. J. Burgerhof, A. Vissink, F. G. M. Kroese, H. Bootsma, Johannes Burgerhof

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)535-536
Number of pages2
JournalAnnals of the Rheumatic Diseases
Volume71
Publication statusPublished - Jun-2012

Cite this